Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.69 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.69 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.69 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620439 | 0.88 | GUCY1B2 (0.76) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16081836 | 0.86 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL29778268 | 0.85 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16082047 | 0.85 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL30114925 | 0.85 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16082035 | 0.84 | GUCY1B2 (0.81) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16082634 | 0.84 | GUCY1B2 (0.76) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16082037 | 0.84 | GUCY1B2 (0.73) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17620438 | 0.84 | GUCY1B2 (0.83) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17484140 | 0.84 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194382-B1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210221793-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC | 2019-09-19 | — | — | US | disclosed |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-3194382-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221793-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 23/4885GUCY1A2 15/4885GUCY1A1 16/4885 |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.